# Open-Label Extension Study of Trofinetide for Rett Syndrome

> **NCT04776746** · PHASE3 · TERMINATED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 77 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** trofinetide

## Key facts

- **NCT ID:** NCT04776746
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-08
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776746, "Open-Label Extension Study of Trofinetide for Rett Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04776746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*